Exploring What's Possible With Stem Cell Therapies

Over the past several years, stem cell research has experienced a significant upswing, evidenced by not only activity in the lab and clinic but also investments industry-wide. The biotech boom is being spurred in large part by in vitro stem cell research driving new precision approaches in tissue engineering, cancer immunotherapies, neurological and endocrine diseases, and much more.

But amid the surge of activity and promise surrounding applications in mesenchymal stem cells, induced pluripotent stem cells and emerging acellular therapies, such as extracellular vesicles, challenges remain in making these advanced therapies production-ready for clinical trials and, ultimately, market entry.

From difficulties in efficiently optimizing cellular expansion and downstream processing to the ongoing need to prioritize cell quality in tandem with cell quantity, these barriers have precluded many bench projects from achieving the milestones necessary for commercial success. The need to expand research cultures to production-ready scale — cost-effectively and quickly — is an ongoing challenge for life science companies.

But new technologies, culturing platforms and materials have made the costs, responsibilities and pressures less cumbersome for lab scientists looking to realize the promise of stem cell therapies while overcoming the many pitfalls.

Here, Corning Life Sciences experts explore the changing landscape of stem cell research and cell therapy production and highlight how emerging solutions have facilitated a new era of more effective and efficient workflows.

Originally published by Industry Drive, Inc.